Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Files Opdivo for Adjuvant Therapy for Esophageal Cancer in Japan
February 19, 2021
- Chugai Re-Files Patent Suit over Edirol, Now Focuses on Crystalline Form
February 18, 2021
- Mitsubishi Tanabe Accelerating Drug Discovery via Open Innovation, Early-Stage Data Sharing
February 18, 2021
- Novo Training Its Sights on Oral Diabetes Market with Rybelsus, Not Switches from GLP-1 Injectables
February 17, 2021
- FoundationOne Approved as a CDx for Pemigatinib: Chugai
February 17, 2021
- Shionogi Pharma Set to Expand CDMO Biz with Continuous Manufacturing, Eyes 10 Billion Yen Sales in FY2024
February 17, 2021
- Stella Pharma Recalls Cancer Radiation Therapy over Flawed Testing at Kyowa CritiCare
February 17, 2021
- BMS Joins Hands with Tokyo Medical and Dental University on Fibrosis Research
February 17, 2021
- Japan’s 1st Humira Biosimilar Hits Market
February 16, 2021
- Number of Flu Patients Tanks to 1/1,000th in January vs Previous 5-Year Average: Survey
February 16, 2021
- Otsuka’s Pharma Sales Up 3.3% in 2020 Driven by 4 Global Brands
February 15, 2021
- Kringle, Keio Univ. Sign Research Pact on HGF Therapy for Spinal Cord Injury
February 15, 2021
- JCR’s Hurler Syndrome Drug Gets Orphan Status in US
February 15, 2021
- Sumitomo Dainippon Cuts Operating Profit Outlook on Napabucasin Flop
February 15, 2021
- JCR Pharma’s JR-141 Gets FDA’s Fast-Track Status
February 12, 2021
- Takeda Files Its 1st Cell Therapy, Darvadstrocel, in Japan
February 12, 2021
- Japan Trial Now Underway for Gene Therapy Luxturna; Eyes Riveted on Its Price Tag
February 12, 2021
- Kobayashi Kako Chief to Resign over Drug Mix-Up, Lousy Manufacturing and Cover-Ups
February 10, 2021
- Chugai to Discuss Filing of Actemra for COVID-19 with Japanese Regulators
February 10, 2021
- Keytruda Top-Seller for 6 Months on End: Encise
February 10, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…